ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年7月10日

查看全文
  • Carolin Siech,
  • Mario de Angelis,
  • Letizia Maria Ippolita Jannello,
  • Francesco Di Bello,
  • Natali Rodriguez Peñaranda,
  • Jordan A. Goyal,
  • Zhe Tian,
  • Fred Saad,
  • Shahrokh F. Shariat,
  • Stefano Puliatti,
  • Nicola Longo,
  • Ottavio de Cobelli,
  • Alberto Briganti,
  • Benedikt Hoeh,
  • Philipp Mandel,
  • Luis A. Kluth,
  • Felix K. H. Chun,
  • Pierre I. Karakiewicz

摘要

Background

To assess cancer-specific mortality (CSM) and other-cause mortality (OCM) rates in patients with rare histological prostate cancer subtypes.

Methods

Using the Surveillance, Epidemiology, and End Results database (2004–2020), we applied smoothed cumulative incidence plots and competing risks regression (CRR) models.

Results

Of 827,549 patients, 1510 (0.18%) harbored ductal, 952 (0.12%) neuroendocrine, 462 (0.06%) mucinous, and 95 (0.01%) signet ring cell carcinoma. In the localized stage, five-year CSM vs. OCM rates ranged from 2 vs. 10% in acinar and 3 vs. 8% in mucinous, to 55 vs. 19% in neuroendocrine carcinoma patients. In the locally advanced stage, five-year CSM vs. OCM rates ranged from 5 vs. 6% in acinar, to 14 vs. 16% in ductal, and to 71 vs. 15% in neuroendocrine carcinoma patients. In the metastatic stage, five-year CSM vs. OCM rates ranged from 49 vs. 15% in signet ring cell and 56 vs. 16% in mucinous, to 63 vs. 9% in ductal and 85 vs. 12% in neuroendocrine carcinoma. In multivariable CRR, localized neuroendocrine (HR 3.09), locally advanced neuroendocrine (HR 9.66), locally advanced ductal (HR 2.26), and finally metastatic neuroendocrine carcinoma patients (HR 3.57; all p < 0.001) exhibited higher CSM rates relative to acinar adenocarcinoma patients.

Conclusions

Compared to acinar adenocarcinoma, patients with neuroendocrine carcinoma of all stages and locally advanced ductal carcinoma exhibit higher CSM rates. Conversely, CSM rates of mucinous and signet ring cell adenocarcinoma do not differ from those of acinar adenocarcinoma.